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1. Introduction 
Epigenetics is characterized as hereditary changes in gene activity and expression that occur 
without alteration in DNA genomic sequence. It is known that epigenetics corresponds 
basically by two majority modifications: DNA methylation and histone modifications. 
Epigenetics events are reversible without primary DNA base sequence changes, resulting in 
possible modulation of the gene expression. The accurate DNA modifications and chromatin 
changes are important to normal embryonic development, to correct tissue cells 
differentiation, to precise cell cycle progression and cell death control. However, since 
epigenetics is also crucial to regulate gene expression, uncontrolled and/or incorrect 
modifications can unbalance the genetic expression profile and result in cellular 
transformation from normal to malignant cells. 
The development of cancer cell is frequently associated with sequential of genetic and/or 
epigenetics hits, resulting in loss- or gain-of-function in genes, which leads to cell 
transformation. At a glance, aberrant global levels of histone modifications as well as 
incorrect methylation gene promoter may lead to the silencing of tumor suppressor genes 
and the activation of proto-oncogenes. Recently, many studies have revealed how 
epigenetics regulation has an implication in the identification of new biomarkers and the 
development of new therapies at several types of cancers. Moreover, nowadays, a series of 
identified epigenetics changes have been used as markers for cancer progression and for 
given prognostic value.  
The field of cancer epigenetics is evolving rapidly in many aspects. In myelodysplastic 
syndrome (MDS), some research groups have been showed the importance to study 
epigenetic alterations as new diagnostic, prognostic and risk stratification biomarkers. The 
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MDS comprises a heterogeneous group of clonal bone marrow disorders characterized by 
varying degrees of pancytopenia, morphological and functional abnormalities of 
hematopoietic cells and increased risk of transformation into acute myeloid leukemia. This 
hematologic malignancy became a model to study the genetics and epigenetics changes 
involved in development stages of leukemia and it is considered a model study to 
tumorigenesis. MDS is viewed as a disease of adults, particularly the elderly. Pediatric MDS 
is an uncommon disorder, accounting for less than 5% of hematopoietic malignancies. Some 
studies in children showed that MDS appears with distinct clinical and laboratory 
characteristics when compared with adults, which may reflect special biological issues of 
MDS during childhood. There are different pathways involved in the pathogenesis of MDS. 
Due to the MDS heterogeneity, little is known about the molecular basis of MDS in adults 
and mainly in pediatric patients. Identification of the underlying genetic and epigenetic 
alterations in MDS may promote proper classification and prognostication of disease and, 
eventually, the development of new therapies. An important point in the epigenetic studies 
is the introduction of new forms of treatment for MDS patients. It is well documented that 
hematopoetic stem cell transplantation (HSCT) is, until now, the only curative treatment for 
MDS, both in adults and in children, but relapse after HSCT is the major cause of treatment 
failure in advanced stages. Other important factors in HSCT are the necessity of 
histocompatibility of donor cells and the age of the patients, sometimes limiting the use of 
this treatment. Thus, it is extremely important detecting biomarkers of disease evolution, 
especially those involved in epigenetic modifications, because news forms of treatment, as 
the use of hypomethylation agents, can be introduced as a better treatment option. 
This chapter will review the advances in the study of epigenetics in cancer, the discovery of 
new epigenetic biomarkers and the development of therapeutic strategies using 
hypomethylation drugs. We will focus the advances in the epigenetic field using the 
myelodysplastic syndrome as a model, since it was demonstrated the importance of 
epigenetics alterations in the pathogenesis of this disease. Finally, we will describe the 
importance of statistical methods to aid the analysis of new diagnostic and prognostic 
epigenetic biomarkers. 
2. The role of epigenetics in cancer 
Epigenetics alterations have been growing as a promisor tool to understand cancer 
development, for better clinical therapy management, to identify new cancer biomarkers, 
which can help in monitoring disease evolution. It is known that epigenetics corresponds 
basically by two majority modifications: DNA methylation and chromatin modifications.  
DNA methylation is a covalent modification of the cytosine ring 5’ position of a CpG 
dinucleotide, whereby a methyl group is deposited on carbon 5 of that ring using S-
adenosyl methionine as a methyl donor. This transfer of methyl group is a replication-
dependent reaction catalyzed by DNA methyltrasferases (DNMTs) (Figure 1). 
Humans DNA methyltransferases are represented basically by three proteins: DNMT1, 
DNMT3A and DNMT3B. In general, DNMT1 are preferentially responsible for the 
methylation of one strand of DNA using as reference the other strand already methylated, 
mechanisms known as de novo methylation. This DNA hemi-methylation activity is 
important to maintain the methylation profile of genomic DNA cells during cellular  
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Fig. 1. DNA methylation. (A) Methyl radical transference from SAM (S-adenosyl-l-
methionine) to 5th carbon of aromatic ring of cytosine nucleotide mediated by DNMT (DNA 
methyltransferase). (B) DNA sequence indicating that only cytosines before guanine will be 
methylate (red arrows). This cytosine/guanine in the methylation studies is also known as 
CpG and the concentration of CpG in some region of DNA sequence is known as CpG 
Island.  
division. DNA hemi-methylation promoted by DNMT1 is crucial for initial stages of 
embryonic development and cell survival. In other hand, DNMT3A and DNMT3B play 
essential role for DNA hemi-methylation or unmethylated with the same level. Catalytic 
methyl-transferase of DNMT3A or DNMT3B is mainly promoted in cytosine preceded by 
guanine at the CpG dinucleotide. DNA methylation is a no random phenomenon. It 
normally occurs at the CG rich DNA sequences (the CpG islands) at promoter regions 
(Robertson et al., 1999; Tabby & Issa, 2010; Worn & Gulberg, 2002). 
DNA methylation is frequently associated to transcriptional gene repression. It has been 
suggested that repression occurs by physically interfering in transcriptional factors binding 
at gene promoter regions, modified by 5’-methylcitosine or by recruiting methylated-DNA 
binding domain (MBD) proteins that block an original site of transcriptional factor. In 
addition, MBD proteins are frequently found associated with histone deacetylases. 
Physiological DNA methylation has been shown important to regulate genetic expression 
during embryonic development, genomic imprinting, X chromosome inactivation and 
cancer (Worn & Gulberg, 2002). 
Chromatin is defined by a DNA and DNA-associated proteins, known as histones, in which 
genomic eukaryotic DNA is packaged. The basic unit of chromatin is called nucleosome, 
which is composed of a small DNA sequence, approximately 147 bases pairs, wrapped on 
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protein octamer of the four core Histones (H2A, H2B, H3, and H4) and linker Histone H1. 
Epigenetics regulation involving chromatin comprises the post-translational modifications 
of histone protein tails. Depending on the kind of histone alteration, chromatin becomes 
compressed or weakens, which results in repression or permission to gene expression 
respectively. The histone complexes can be heterogeneous post-translational modified; it 
comprises methylation, acetylation, phosphorylation and ubiquitinylation. These distinct 
levels of combinatory histone modifications possibilities lead to regulation of gene 
transcription, a process called “histone coding”. These histone changes are promoted by a 
series of distinct proteins, such as histone acetyl transferases (HAT), histone deacetylases 
(HDAC) and Polycomb group (PcG) proteins (Marks & Dokmanovic, 2005). The HAT and 
HDAC catalyze the transference of acetyl radical to histone tails (Kleff et al., 1995). 
Commonly, chromatin acetylation promotes the transcription factors access to DNA 
consensus sequences. Therefore, chromatin acetylation is frequently related to increase of 
transcriptional gene activity (Figure 2). Acetylation is not a random event and occurs in H3 
and H4 tails, mainly on lysine residue, such as H3K4 and H3K14 (Agalioti et al., 2002). 
 
Fig. 2. Chromatin structure and histone tails modifications. Two mainly chromatin 
modifications, acetylation (AC) and methylation (MET). Acetylation is direct related to loose 
of chromatin compression which allows transcriptional factors access to DNA molecule and 
transcript its target gene. Methylation of histone tails is associated to chromatin compression 
and, as consequence, block the transcriptional factors access. 
Among chromatin modifiers, Polycomb Group (PcG) proteins have been established as 
classical players of epigenetics regulation. PcG genes were discovered at experiments of 
mutations in Drosophila development (Lewis, 1978). In these studies, PcG proteins were 
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found to control the activities of homeotic genes, which determine segmentation and 
structures body during development (Ingham, 1985). Several PcG orthologues genes were 
found in humans (van Lohuizen et al., 1991). PcG proteins are subdivided into two classes 
designed as Polycomb Repressive Complex: PRC1 and PRC2. The number of PcG proteins 
suggests a greater complexity of functions on the chromatin regulating. In this context, PcG 
have been reported to act in a myriad of histone modifications such as, ubiquitylation, 
sumoylation and methylation (Margueron & Reinberg, 2005). PcG proteins perform a critical 
role in gene regulation. PCR2 and PCR1 are considered to be involved in the initialization 
and maintenance of the repression of the gene transcription, respectively. PCR2 comprises 
the core components enhancer of zeste-2 (EZH2), embryonic ectoderm development (EED), 
and suppressor of zeste 12 (SUZ12), while PCR1 consists in a ring finger protein 1 (RING1), 
B lymphoma Mo-MLV insertion region 1 (BMI1) and chromobox homologue 2/4/8 
(CBX2/4/8). EZH2 is the catalytic subunit of PRC2. It is a highly conserved histone 
methyltransferase that targets lysine 27 of histone H3. This methylated H3-K27 is usually 
associated with silencing of genes involved in differentiation. In addition, EZH2 is required 
for DNA methylation of EZH2- target promoters, serving as a recruitment platform DNA 
methyltransferases. SUZ12 is a recently identified PcG protein that, together with EED, is 
essential to maintaining the repressive function of PRC2. RING1 catalyzes the mono 
ubiquitylation of histone H2A at lysine 119. The H2AK 119 ubiquitylation likely increases 
chromatin compaction and, thus, interferes with the access or action of transcription factors. 
BMI 1 is mostly detected in stem cells and progenitors and takes part in stem cell 
proliferation and self-renewal (Bantignies & Cavalli, 2006; Levine et al., 2004; Rajasekhar & 
Begemann, 2007). 
Cancer development is a consequence of multi-step molecular and cellular events that 
transform normal to malignant cell. During this process genetic and epigenetic alterations 
are involved. In recent years, several studies have indicated how epigenetics regulation has 
an implication in the identification of new biomarkers and the development of new 
therapies in a majority of cancers. Several evidences of oncogenes and tumor supressor 
genes DNA methylation indicated the importance of these epigenetics changes under 
expression control. DNA hypomethylation was directly related to the overexpression of Raf, 
c-Myc, c-Fos, c-H-Ras and c-K-ras oncogenes and tumor liver formation (Rao et al., 1989). 
Hypermethylation of tumor suppressor genes has also been demonstrated. For example, 
DNA methylation interferes in the expression of key cell cycle checkpoints genes: p16INK4A, 
p15INK4B, Rb, p14ARF. These are the most studied genes used to correlate methylation and cell 
cycle control in several cancer types (Esteller, 2011). DNA or chromatin epigenetic 
alterations have been directly related to molecular changes to cancer development. Some 
epigenenetic modifications have been usefulness as biomarkers to aid in the clinical-
therapeutic decision. For instance, APC and GSTP1 gene methylation and 
H3K4me/H3K4me2/H3K18Ac chromatin modifications have been used to predict response 
to therapy and prognostic information in prostate cancer (Henrique & Jerónimo, 2004; 
Jerónimo et al., 2011).  
The potential reversibility of epigenetics states offers exciting opportunities for new cancer 
drugs that can reactivate epigenetically silenced tumor-suppressor genes. Blocking either 
DNA methyltransferases or histone deacetylase activity could potentially inhibit or reverse 
the process of epigenetic silencing (Kelley et al., 2010). DNA demethylating drugs (DMI), as 
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5-azacytidine and 5-aza-2'-deoxycytidine, have been indicated as a promising new treatment 
for cancer (Streseman & Lyko, 2008). Histone deacetylase inihibitors (HDACs) have also 
been analyzed at clinical protocols for solid tumors (breast, non-small lung cells, prostatic 
cancer) and mainly for hematological malignancies (myelomas, leukemias and 
myelodysplastic syndrome) (Ellis et al., 2009; Graham et al., 2009; Hrebackova et al., 2010; 
Razak et al., 2011). In figure 3, we can see that the epigenetic therapy can “re-programmed” 
gene expression patterns. 
 
Fig. 3. Epigenetic therapy acting in the effects of DNMT or HDAC. Inhibitors of DNMT 
(DNA methyltransferase) or HDAC (histone deacetylases), as DMI (DNMT inhibitor) and HDI 
(Histone Deacetylase Inhibitor), respectively, induce the reprogramming expression by 
chromatin decompression. In summary, these inhibitors act mainly cell-cycle, apoptosis and 
differentiation related genes. 
3. Myelodysplastic syndrome 
The primary myelodysplastic syndrome (MDS) comprises a heterogeneous group of clonal 
bone marrow disorders, characterized by abnormal cellular morphology (dysplasias) and 
defects in the normal differentiation and prolileration of hematopoietic precursors. These 
www.intechopen.com
Epigenetics in Cancer: The Myelodysplastic Syndrome as a  
Model to Study Epigenetic Alterations as Diagnostic and Prognostic Biomarkers 
 
25 
defects result in ineffective hematopoiesis (bone marrow failure) and an increased risk of 
transformation into acute myeloid leukemia (AML) (Davids & Steensma, 2010; Jadersten & 
Hellström-Lindberg, 2008). MDS is viewed as a disease of adults, particularly the elderly. 
Pediatric MDS is an uncommon disorder, accounting for less than 5% of hematopoietic 
malignancies (Elghetany, 2007; Niemeyer & Baumann, 2008). The primary MDS presents a 
natural history since an indolent disease with long time of duration to a rapid progression to 
AML in few months (Nishino & Chang, 2005). The diagnosis is done initially by the 
hemogram indicating one or more cytopenias in peripheral blood like anemia, neutropenia 
and thrombocytopenia. The analysis is performed by the myelogram and bone marrow 
biopsy to identify dysplastic cells, the possible presence of blasts, characterizing later stages 
of the disease, and the presence of abnormal localization of immature precursors (ALIP). 
The bone marrow of MDS patients is usually hypercellular or normocellular, but there are a 
small number of cases with hypocellular bone marrow. In cases where bone marrow is 
hypocellular, it is recommended to perform differential diagnosis of severe aplastic anemia 
(SAA) and paroxysmal nocturnal hemoglobinuria (PNH). In these cases, important 
diagnostic tools, like the cytogenetics and the immunophenotyping, aid this diagnosis 
(Bennett & Orazi, 2009; Wong & So, 2002). The apparent paradox of hypercellular bone 
marrow and peripheral blood cytopenias was clarified by studies showing that MDS 
patients have increased rates of apoptosis in bone marrow in early stages of the disease 
(Parker et al., 2000). 
The primary MDS diagnosis is considered a difficult clinical practice, because there are 
several clinical manifestations which may present a clinical and histological picture quite 
similar to MDS, such as nutritional deficiencies, infections and congenital conditions. It is 
necessary a differential diagnosis, where the presence of cytogenetic clonality helps in the 
diagnosis of primary MDS and contributes for the prognosis (Haase et al., 2007; Olney & Le 
Beau, 2009; Solé et al., 2005; Tiu et al., 2011). Nevertheless, there are cases with normal 
karyotype, so it is important to characterize molecular biomarkers to aid the MDS diagnosis. 
Because the primary MDS is a disease extremely heterogeneous, the definition of prognostic 
factors are often difficult. Thus, in the later years, it has been extensively discussed the 
classifications and prognostic scales for adult and pediatric patients. 
3.1 Classifications and prognostic scores systems in myelodysplastic syndrome 
Until 1980, the MDS included a variety of hematologic abnormalities classified as 
syndromes or pre-leukemic states. However, these denominations were unsatisfactory, not 
grouping all the patients who showed an ineffective hematopoiesis and not progressed to 
acute leukemia, occurring complications because of the cytopenias leading to death. The 
term “pre-leukemia” disappeared and the term myelodysplstic syndrome became widely 
accepted in 1982 with the FAB classification. 
3.1.1 FAB classification 
In 1982, the FAB group (French, American and British group) proposed a classification for 
primary MDS into five subgroups: refractory anemia (RA), refractory anemia with ringed 
sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory anemia with 
excess blasts in transformation (RAEB-t) and chronic myelomonocytic leukemia (CMML). 
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This classification was based on morphological characteristics and the percentage of blasts 
in the bone marrow and peripheral blood (Table 1) (Bennett et al., 1982). 
Subgroup 
Monocytes (l) 
peripheral blood 
Ringed Sideroblasts 
(%) bone marrow 
Blast cells (%) 
Auer 
rods 
bone 
marrow 
peripheral 
blood 
bone 
marrow 
RA No < 15 < 1 < 5 No 
RARS No > 15 < 1 < 5 No 
RAEB No No < 5 5 - 20 No 
RAEB-t No No > 5 20 - 30 Yes or No 
CMML > 1000 No < 5 < 20 No 
Table 1. Classification of Myelodysplastic Syndrome according to the FAB Group in 1982. 
As we can notice, this classification suggests multiple steps during the evolution from MDS 
to acute leukemia, being the initial stages the RA and RARS and the advanced stages the 
RAEB, RAEB-t and CMML. Since it was introduced, several studies have shown the 
usefulness of the FAB classification, both for monitoring a large number of patients with 
primary MDS, allowing comparisons between different studies, as for the treatment of 
patients. However, to determine a precise prognosis this classification still has some 
problems especially within initial subgroups, RA and RARS. The term "refractory anemia" is 
not always adequate, and anemia is only one of the three cytopenias in MDS. The CMML 
presents features of MDS and myeloproliferative diseases, so their inclusion in MDS 
classification has been discussed in more recent classifications like the World Health 
Organization (WHO) (Harris et al., 2000; Malcovati & Nimer, 2008). 
3.1.2 WHO classification 
The classification of the World Health Organization (WHO) was established in 2000 and 
used many concepts and definitions of the FAB classification and also the knowledge of the 
cytogenetic and molecular features to improve the definition of subgroups, as well as 
clinical relevance in order to improve diagnostic criteria and improve the prognosis 
definition (Harris et al., 2000). The main difference between the two classifications is the 
disappearance of the subgroup RAEB-t, considered the evolution to AML from 20%of blasts 
in the bone marrow. The classification system proposed by WHO was reviewed in 2008 and 
consider the subgroups described in Table 2. In this new classification the subgroup CMML 
is regarded as a myeloproliferative disorder. The WHO categories have several important 
clinical implications (Brunning et al., 2008). Patients with unilineage dysplasia have a 
favorable outcome compared to patients with multilineage dysplasia (Jadersten & 
Hellstrom, 2008). The presence of del(5q) strongly correlates to the probability of response to 
lenalidomide (Oliva et al., 2010). 
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Subgroup Peripheral Blood Bone marrow 
Refractory cytopenias 
with unilineage 
dysplasia (RCUD) 
Unicytopenia or 
bicytopenia; 
No or rare blasts (<1%) 
Unilineage dysplasia;
≥10% of the cells of the affected lineage 
are dysplastic; <5% blasts; 
<15% ring sideroblasts
Refractory anemia 
with ring sideroblasts 
(RARS) 
Anemia; 
No blasts 
Erythroid dysplasia only;
<5% blasts; 
≥15% ringed sideroblasts
Refractory cytopenia 
with multilineage 
dysplasia (RCMD) 
Cytopenia(s);  
or rare blasts (<1%);  
No Auer rods; 
monocytes <1 x 109/ L  
Dysplasia in ≥10% of cells in two or 
more myeloid lineages; 
<5% blasts; 
No Auer rods;  
±15% ring sideroblasts
Refractory anemia 
with excess blasts-1 
(RAEB-1) 
Cytopenias;
<5% blasts; 
No Auer rods; 
monocytes <1 x 109/ L 
Unilineage or multilineage dysplasia; 
5-9% blasts; 
No Auer rods 
Refractory anemia 
with excess blasts-2 
(RAEB-2) 
Cytopenias; 
5-19% blasts; 
± Auer rods;  
monocytes <1 x 109/ L  
Unilineage or multilineage dysplasia;  
10–19% blasts; 
± Auer rods 
Syndrome 5q- 
Anemia; 
No or rare blasts (<1%); 
Platelet count usually 
normal or increased 
Normal to increased megakaryocytes 
with hypolobated nuclei; 
<5% blasts;  
Isolated del(5q) cytogenetic 
abnormality;  
No Auer rods
Myelodysplastic 
syndrome, 
unclassified (MDS-U) 
Cytopenias; 
Blasts ≤1% 
Dysplasia in <10% of the cells in one or 
more myeloid lineages; 
<5% blasts; 
No Auer rods 
Table 2. The WHO 2008 Classification of MDS. 
3.1.3 Classification of myelodysplastic syndrome in childhood 
Some studies have shown differences in morphological, cytogenetic, molecular and clinical 
manifestations of primary MDS in childhood that affect their inclusion in traditional 
classification systems (FAB and WHO), based mainly on adult patients. The rarity of 
childhood MDS and the heterogeneous nature of the disease have further contributed to the 
difficulties in classifying this disease (Hasle &Niemeyer, 2011). In 2003, Hasle and 
colleagues proposed a pediatric approach to the WHO classification of myelodysplastic 
syndrome: 1- MDS occurring both “de novo” and secondary, including the subtypes 
refractory cytopenia (RC), RAEB, and RAEB-t.; 2- a group of myelodysplastic/ 
myeloproliferative disorders with Juvenile Myelomonocytic Leukemia (JMML) as the most 
common disorder of this category; 3- myeloid leukemia of Down syndrome (DS), a disease 
with distinct clinical and biological features, encompassing both MDS and AML. In this 
classification, the minimal diagnostic criteria are: unexplained cytopenia (neutropenia, 
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thrombocytopenia or anemia), at least bilineage morphologic myelodysplasia, acquired 
clonal cytogenetic abnormality in hematopoietic cells and blast cells number ≥5%. However, 
this classification has also been widely discussed because not all patients have chromosomal 
abnormalities, especially in the early stages of the disease (Niemeyer & Baumann, 2008). 
And in 2009, JMML was considered a myeloproliferative disorder (Hebeda & Fend, 2009). 
3.1.4 Prognostic score system in myelodysplastic syndrome 
Parallel to the improvement of classification systems, due to the large variability in survival 
within the same subgroup of primary MDS, it was necessary to develop score systems for 
prognostic stratification of risk groups, assisting the choice of treatment. The score system 
for risk groups most widely used for primary MDS is the International Prognostic Score 
System (IPSS) (Greenberg et al., 1997). The IPSS considers the percentage of bone marrow 
blasts, the number of peripheral blood cytopenias and the cytogenetic, the prognostic factors 
most important in relation to survival time and about the rate of leukemic transformation. 
The IPSS recognized four risk groups: low risk, intermediate 1, intermediate 2 and high risk. 
This system considers three categories for cytogenetic analysis: low risk [normal karyotypes, 
-Y, del(5q) and del(20q)]; high risk (alterations involving chromosome 7 and complex 
karyotypes) and intermediate risk (other chromosome abnormalities) . 
The IPSS has gained prominence for its clinical utility due to the fact that it allows the 
prediction of disease progression in independent series of previously untreated patients. 
However, despite its importance, this system has some limitations like the risk groups in 
relation to karyotype. In some studies, trisomy 8, for example, is often associated with 
disease progression (Fernandez et al., 2000; Garcia-Manero, 2010; Solé et al., 2000). However, 
the IPSS classifies this chromosomal alteration with intermediate prognosis. Other 
important point is related to normal karyotypes that are associated, in some cases, to shorter 
survival when compared to some chromosomal alterations like: -X, del(5q), del(20q), +21 
(Haase, 2008). So, the introduction of molecular data will help to characterize new 
prognostic factors and use these biomarkers to contribute in understanding the 
development of MDS and its evolution to AML. 
3.2 Pediatric and adult myelodysplastic syndrome 
Although the pediatric MDS shows dysplastic features and ineffective hematopoiesis, such 
as MDS in adults, clinical characteristics, the presence of constitucional genetic associated 
abnormalities and characterization of chromosomal changes have reflected a different 
biological question of MDS in childhood (Elghetany, 2007; Polychronopoulou et al., 2004). 
The main differences between childhood and adult MDS are: the incidence of RARS cases 
are extremely rare in pediatric patients and in adults consists of about 25% of cases; the 
monosomy 7 is the chromosomal alteration most frequent in pediatric patients and in adults 
is the deletion of the long arm of chromosome 5; the therapeutic possibilities in adult 
patients is generally limited due to advanced age and usually it is indicated a palliative 
therapy, whereas, in children with MDS, the main therapy indicated is curative; the 
allogeneic hematopoetic stem cell transplantation (Halse & Niemeyer, 2002). Some clinical 
features are different between adults and children with MDS and the factors that predict 
survival or progression in adults are of little value to children. So, the IPSS has limited value 
for pediatric MDS (Hasle et al., 2004).  
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In relation to cytogenetic studies, they showed a key role in the diagnosis of the suspected 
cases of pediatric MDS, being used to confirm the clonal nature of this disease (Sasaki et al., 
2001). The monosomy 7 is the most common chromosomal abnormality in these patients 
(Figure 4). This alteration is associated with poor prognosis and a rapid progression to AML 
(Aktas et al., 2006; Fernandez et al., 2000; Sasaki et al., 2001).  
 
BA
 
 
Fig. 4. (A) Karyotype of bone marrow cell by GTG-banding showing: Monosomy 7. (B) FISH 
analysis showing monosomy 7 using the probe: LSI D7S486 spectrum orange/ CEP 7 
spectrum green, Vysis, Inc. Downers Grove, USA. It may be observed in the interphases 
nucleus four signals characterizing normal cells (yellow arrows) and others interphases 
nucleus showing two signals (white arrows), confirming the loss of the chromosome 7.  
The molecular mechanisms involved in MDS mainly, in childhood, are not well defined. A 
recent molecular study of TP53 and c-fms genes showed no mutations in children with MDS. 
The presence of mutations in onocogene N-ras also occurs in a very low frequency in 
childhood MDS. However, mutations in TP53, c-fms and N-ras genes are involved in the 
development and evolution from MDS to AML in adult patients (Fernandez et al., 1998; 
Jekic et al., 2004, 2006). These results suggest that some molecular mechanisms involved in 
the pathogenesis of MDS in children are different from those seen in adults. It has been 
observed the importance of epigenetic alterations in the pathogenesis of MDS, but the 
majority of these studies is focused in adult patients. Few studies showed the epigenetic 
alterations in children (Hasegawa et al., 2005; Rodrigues et al., 2010; Vidal et al., 2007). 
Rodrigues and colleagues, 2010, suggested that methylation of p15INK4B and p16INK4A genes 
are epigenetic alterations in pediatric MDS patients and, as in adult patients, are later events 
associated with the leukemogenesis process in MDS.  
3.3 Cytogenetics and epigenetics alterations in myelodysplastic syndrome 
The discovery of non-random chromosomal abnormalities in primary MDS confirmed the 
clonality, providing a way to identify the malignant clone and point out some oncogenes 
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and tumor suppressor genes possibility involved in the development and progression of 
disease. The cytogenetics evaluation of a bone marrow sample from patients with MDS 
has become an integral part of clinical care. The clonal cytogenetic alterations can be 
detected in 30-50% of adult patients with primary MDS. In pediatric patients this 
incidence is 50-70% of the cases. These changes range from a single numerical or 
structural changes to complex genomic lesions involving three or more different 
chromosomes. The most frequent chromosomal abnormalities in MDS are: del(5q), 
del(7q)/-7, +8, del(11q), del(12p), del(17p), del(20q) and loss of Y chromosome (Bejar et 
al., 2011; Fernandez et al., 2000; Haase, 2008).  
The frequency of cytogenetic abnormalities increases with the severity of disease as well as 
the risk of leukemic transformation. In this group, unfavorable chromosomal abnormalities 
are frequently found as complex abnormalities or karyotypes including monosomy 7 or 
trisomy 8 (Bacher, 2010; Fernandez et al., 2000). A normal karyotype is found in 30-60% of 
patients with MDS. This group of patients is almost certainly genetic heterogeneous, 
probably the leukemogenic alterations occurred at the molecular level and were not 
detectable with standard cytogenetic methods (Greenberg et al., 1997; Onley & Le Beau, 
2009). 
In MDS, some studies suggest some genes involved with specific chromosome alterations, 
as the del(5q). The 5q syndrome represents a distinct clinical entity characterized by a 
del(5q) as the sole karyotypic abnormality. The 5q syndrome occurs commonly in women. 
The initial laboratory findings are usually a macrocytic anemia with a normal or elevated 
count. The diagnosis is usually RA. On bone marrow examination, abnormalities in the 
megakaryocytic lineage (particularly micromegakaryocytes) are prominent. These patients 
have a favorable prognosis, with low rates of leukemic transformation and a relatively long 
survival of several years. The loss of a single copy of the RPS14 gene may be involved in the 
MDS 5q- pathogenesis. The RPS14 is an essential component of the 40S subunit of ribosomes 
and ribosomes synthesis is impaired in CD34 + cells from 5q syndrome patients (Onley & Le 
Beau, 2009).  
The role of cytogenetic analysis in MDS is an important factor for establishing the diagnosis, 
prognosis and therapeutic plan and the follow up of altered clinical behavior of the disease. 
The chromosomal abnormalities have not only provided insights into prognosis but also 
into the molecular pathogenesis of this heterogeneous disease. The type of chromosomal 
abnormality (unbalanced, most commonly the result of the loss of a whole chromosome or a 
deletion of a part of a chromosome) in primary MDS indicates that the main class of genes 
involved in the pathogenesis of this disease is the tumor suppressor genes. The mechanism 
involved in the inactivating tumor suppressor genes are deletions, mutations and epigenetic 
alterations as the DNA methylation.  
Three main epigenetic events regulate tumor-associated genes: 1) the aberrant 
hypermethylation of tumor suppressor genes, 2) post-translational modifications of histones 
and 3) post-transcriptional modifications by regulatory miRNA. The underlying causes of 
the pathogenesis of MDS remain to be fully elucidated. Knudson model of the “two hits” 
provides the basis of the concept of a multistep pathogenesis in the development of MDS, 
where loss or inactivation of only one allele is not sufficient to result in the development of 
tumors or expansion of a malignant clone. In fact, MDS in early stages with its relatively 
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slow (but with increased tendency) to AML progression represents a prototype of the 
multistep concept in leukemogenesis with accumulation of cellular and molecular defects 
during the initiation and disease progression (Vigna et al., 2011).  
Recent studies have revealed that DNA methylation and histone modification may be 
controlled by Polycomb-group (PcG) proteins, which may give new clues toward 
understanding the epigenetic mechanisms of MDS. PcG family members, such as EZH2, 
RING1 and BMI-1, are essential for the self-renewal and proliferation of normal cells. 
However, the induced over expression of these proteins can drive tumorigenesis. In MDS 
patients, the expression of EZH2, RING1 and BMI 1 were positively correlated with the IPSS 
prognostic scoring system, suggesting that the over expression of each of these three genes 
is a negative prognostic indicator (Xu et al., 2011). The EZH2 expression level was positively 
correlated with a reduction of peripheral blood cells, which was likely to reflect the severity 
of ineffective hematopoiesis. Molecular analyses of EZH2 showed that deletions, missense 
and frameshift mutations strongly suggest that EZH2 is a tumor suppressor gene in MDS 
pathogenesis (Nikoloski et al., 2010). Other mutations have been identified in the genes that 
regulate endogenous methylation networks within cells including IDH1/2, TET2 and 
DNMT3. The relevance of these lesions in being able to predict response to epigenetic 
modulators and their correlation with epigenetic signatures in MDS are beginning to emerge 
(Tan & Wei, 2011). 
In MDS, aberrant silencing due to promoter hypermethylation involves genes encoding 
cell adhesion molecules, cell cycle regulation and tumor suppressor genes possibly 
leading to dysregulation of hematopoiesis. It has been shown in MDS a high prevalence of 
methylation for the tumor suppressor genes p15INK4B, cadherin 1 (CDH1), death associated 
protein kinase (DAPK) and suppressor of cytokine signaling (SOCS-1). Some methylation 
patterns in specific genes in MDS can predict poor prognosis even in early stage of the 
disease (Aggerholm et al., 2006; Bejar et al., 2011; Vigna et al., 2011). Hence, epigenetic 
changes have been implicated as potential mechanisms in the pathogenesis and 
progression of MDS, which has already resulted in promising therapeutic approaches in a 
subset of patients. 
3.4 Methylation changes in myelodysplastic syndrome: Diagnostic and therapeutical 
implications  
Different studies in MDS showed the importance of methylation changes during the clinical 
evolution of disease to AML. So, the identification in the diagnosis of these alterations is 
important for risk group stratification. Aberrant DNA methylation is view as a poor 
prognostic feature in MDS. For example, p15INK4B and p16INK4A genes are members of cyclin 
dependent kinase inhibitors family which controls the progression of cell cycle from G1 to S 
phase. The products of these genes regulate RB function by modulating the complexes of 
cyclin D-CDK4/6 which can phosphorylate and inactive the RB protein, and set up an 
important pathway for inhibiting cell growth (Serrano et al., 1996; Shimamoto et al., 2005). 
In addition, p15INK4B has been suggested to act as a regulator of proliferation and 
differentiation in myelo-monocytic and megakaryocytic lineages by arresting the cell cycle 
(Sakashita et al., 2001; Teofili et al., 2000). Therefore, the silencing of these genes via aberrant 
methylation is a critical event in leukaemogenesis. In MDS, aberrant methylation of p15INK4B 
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gene has been related to more aggressive subtypes of disease and it is a possible biomarker 
of disease evolution (Quesnel et al., 1998; Rodrigues et al., 2010).  
Another gene methylated in MDS is the death-associated protein kinase (DAP-kinase), a 
proapoptotic serine/threonine kinase. The analysis of the methylation status of DAP-kinase 
in bone marrow samples from patients with MDS at the time of initial diagnosis showed 
that hypermethylation of DAP-kinase was significantly correlated to loss of DAP-kinase 
expression. Alteration in the apoptotic response due to the loss of DAP-kinase function may 
be an early event in the transformation pathway to secondary leukemia via myelodysplasia 
(Wu et al., 2011).  
The mechanistic bases of CIMP (CpG island methylator phenotype) in MDS remains 
unknown. One proposed mechanisms involves aberrant recruitment of DNA 
methyltransferases to CpG islands and/or loss of methylation protection. Another possible 
explanation is that hypermethylation may not be directly linked to the methylation 
machinery, but rather reflects environmental exposures (Shen et al., 2010). 
The reversible character of epigenetic alterations (in contrast to genetic changes) was an 
important point for the development of therapeutic strategies evolving various epigenetic 
components for anticancer therapy. So, in MDS, the characterization in the diagnosis of 
epigenetic biomarkers of disease evolution may indicate the use of hypomethylating drugs 
in this group of patients. 
A large number of treatments has been used in adults and children with primary MDS, with 
the goal of eliminating the cytopenias as well as to recover hematopoiesis. One of the 
therapies used is the support that involves blood transfusions, antibiotics, growth factors 
alone or in combination, cyclosporin or anti-lymphocyte globulin (ATG) are also used in 
patients with hypocellular bone marrow. In more advanced MDS subtypes (RAEB, RAEB-t), 
in some cases, it has been used the chemotherapy. The allogeneic hematopoietic stem cell 
transplantation (HSCT) is the only curative therapeutic option for patients with MDS, 
however, its use is limited to patients up to 55 years old and patients who have 
histocompatible donors (Giralt et al., 2005; Kindwall-Keller & Isola, 2009). For children with 
MDS, allogeneic HSCT is considered as the best treatment option (Niemeyer & Kratz, 2008).  
With the delineation of the characteristics that drive the biological phenotype of MDS, new 
drugs introduced in the treatment of this disease have shown a great therapeutic potential, 
such as the hypomethylant agents, called methyltransferase inhibitors (IMT). The 
representatives of this class include azacitidine (5-azacytidine) and decitabine (5-aza 2 
'deoxycytidine). Both are incorporated into DNA and then irreversibly bind and inhibit the 
action of DNA methyltransferase. This interaction results initially in a semi-methylated 
DNA. However, after further cell cycles, it becomes completely unmethylated. The action of 
these drugs leads to reactivation of epigenetically repressed genes, such as tumor 
suppressor genes. Initial results showed that patients with higher-risk MDS have an 
increased time to AML transformation and an increase of survival time (Atallah et al., 2007; 
Fenaux et al., 2009; Silverman & Mufti, 2005). The decitabine and azacytidine are approved 
for treatment of patients with int-2 and high-risk MDS. Demethylating agents seem to be the 
best choice for elderly patients with MDS, even in case of high risk cytogenetic changes in 
karyotype, like monosomy 7 (Gurion et al., 2010; Szmigielska-Kaplon & Robak, 2011). 
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Some studies have shown that reduced methylation overtime was correlated with better 
clinical response for patients during decitabine treatment. But, further studies of 
methylation dynamics, both before and after treatment, will be useful to determine the 
ability of epigenetic biomarkers to direct the treatment and may predict for the success 
(Shen et al., 2010). However, in some clinical trials, it was found that a number of patients 
does not respond to decitabine initially (primary resistance) and most patients, who initially 
respond to decitabine treatment, eventually relapse (secondary resistance) despite continued 
therapy. Clinical response to hypomethylating drugs in vivo is complex and may involve 
differentiation and immune activating components. Cytogenetic analysis showed that MDS 
patients after relapse using decitabine showed evolution in 20% patients with abnormalities 
such -7, del(16q) and +8 (Qin et al., 2011). 
The understanding of the epigenetic changes characteristic of the malignant phenotype also 
permit the development of drugs that are able to target other regulators of chromatin 
conformation that contribute to aberrant gene transcription and dysregulated cell growth. 
The histone deacetylase inhibitors (HDAC) belong to one class of therapeutics developed 
using this paradigm. HDAC inhibitors modulate gene expression by inhibiting the 
deacetylation of histone lysine tails, relaxing the chromatin structure by decreasing the 
interaction between positively charged lysine tails of histones and negatively charged DNA. 
Although responses using HDAC inhibitors alone in MDS have been modest, preclinical 
data drives clinical trials in which they are utilized in combination with DNA 
methyltransferase inhibitors. Combination therapy offers the possibility of hematologic 
improvement and remission to MDS patients with previously untreatable disease (Vigna et 
al., 2011).  
DNA methyltransferase inhibitors (hypomethylating agents) have emerged as options for 
the treatment of patients with MDS. These drugs lead to the progressive loss of methylation 
and reversal of gene silencing. In addition to their differentiation-inducing activity, these 
agents also have direct cytotoxic effects (Gurion et al., 2009). Currently available DNA 
methylation blocks all DNMTs. One of the main problems in using DNMT-Is in therapy is 
activation of cancer-promoting genes as well as other disease-promoting genes by 
hypomethylation. Recent studies suggest that there might be differences in the target 
specificity of different DNMTs. It is important to characterize the cancer related genes 
regulated by each of the DNMTs and develop DNMT gene-specific inhibitors. Moreover, 
treatment duration and maintenance therapy of using these agents require further 
investigation (Vigna et al., 2011).  
3.5 DNA methylation alterations as diagnostic and prognostic biomarkers 
Epigenetic transcriptional silencing of genes required for proliferation and differentiation of 
the hematopoetic cells are likely to contribute to the leukemogenic event underlying MDS. 
Altered DNA methylation patterns of some genes are not only of importance to our 
understanding of the molecular pathogenesis of the MDS, but may also serve as novel 
indicators for the diagnosis, the prognosis and the prediction of response to therapy. We can 
see in table 3 some genes that are methylated in MDS and are suggested as possible 
biomarkers that may aid the diagnosis and the prognosis. 
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Genes Function 
MDS Incidence of 
aberrant methylation 
Role in MDS 
Pathogenesis / 
Prognosis 
p15INK4B 
 
p16INK4A 
Members of the cyclin-
dependent kinase 
(CDK) inhibitor family. 
They play an 
important pathway for 
inhibiting cell growth. 
Localization: 9p21 
p15INK4 - adult 
patients :  
61% (25/41); pediatric 
patients:  
32% (15/47) ; 
p16INK4A - adult 
patients : 37% (15/41) 
pediatric patients: 8% 
(4/47) 
High incidence in 
RAEB and RAEB-t. 
Hypermethylation in 
both genes are 
involved in evolution 
from MDS to AML 
and confers a poor 
prognosis. 
(Rodrigues et al., 
2010) 
CDH-1 
(E-cadherin) 
Homotypic cell-cell 
adhesion protein, 
involved in cell-
proliferation. 
Localization: 16q22 
adult patients : 39% 
(16/41) 
Occurs in the various 
subgroups of MDS 
with higher incidence 
in RAEB and RAEB-t. 
(Solomon et al., 2008) 
SOCS-1 
(suppressor 
of cytokine 
sinaling) 
Member of stat-
induced STAT 
inhibitor (SSI), also 
known as a suppressor 
of cytokine signaling 
(SOCS) family. 
Localization: 16p13 
adult patients : 31% 
(27/86) 
Higher risk of 
leukemic 
transformation. 
(Brakensiek et al., 
2005) 
DAPK1 
(death 
associated 
protein 
kinase) 
DAPK1 is a 
serine/threonine 
kinase, a positive 
mediator of gamma-
interferon induced 
programmed cell 
death. Localization: 
9q34.1 
adult patients : 42,3% 
(33/78) 
Associated with 
unfavorable 
cytogenetic risk 
group. Poor 
prognosis. 
(Xu et al., 2011) 
FHIT 
(fragile 
histidine 
triad) 
Fragile histidine triad 
gene member of a 
superfamily HIT of 
nucleotide binding 
proteins. Localization: 
3p14.2 
adult patients : 47,2% 
(26/55) 
Advanced stages of 
MDS  
(RAEB, RAEB-t). 
Disease progression. 
(Lin et al., 2008) 
 
RIZ-1 
(retinoblasto
ma protein-
interacting 
zinc finger 
gene) 
Induce cell cycle arrest, 
apoptosis. 
Localization: 1p36 
adult patients: 50% 
(17/34) 
No statistically 
differences in low and 
high risk, it is 
relatively early event 
in MDS. 
(Mori et al., 2011) 
Table 3. Methylation alterations in genes involved in the pathogenesis of MDS. 
www.intechopen.com
Epigenetics in Cancer: The Myelodysplastic Syndrome as a  
Model to Study Epigenetic Alterations as Diagnostic and Prognostic Biomarkers 
 
35 
4. Statistical analysis of epigenetics biomarkers 
Biomarkers have become important tools for diagnosis and treatment of a wide range of 
illnesses, including cancer. Early detection of cancer through biomarkers will allow for the 
development of new therapeutic procedures in order to increase survival rate of patients 
diagnosed with cancer. To help the evaluation of new biomarkers for medical practice, we 
use statistical methods. In this section, we shall discuss statistical techniques for biomarkers 
evaluation in the myelodysplastic syndrome (MDS). While the application of the methods 
presented is on biomarkers in MDS, the content of this section can be applied to any medical 
research. 
The main mathematical concept necessary to understand statistical methods is probability. 
Although earlier work on the subject was done by the Italian mathematician Giralamo 
Cardano (1501-1576), the investigation of probability as a branch of Mathematics sprang 
about 1654 with two great French mathematicians: Blaise Pascal (1623-1662) and Pierre 
Fermat (1601–1665). Both Pascal and Fermat were interested in predicting outcomes in the 
games of chance popular among the French nobility of the mid-seventeenth century. Of 
course, we shall not do a discourse on probability. But we need to say that the theory of 
probability underlies the procedures in inferential statistics, which is very useful to 
medicine and other disciplines in the health field. In our exposition, we will try to avoid 
mathematical formulas and theorems. 
4.1 Descriptive statistics and inferential statistics 
Statistics is a branch of Mathematics. The word “statistics” derives from the Latin word 
status, meaning “manner of standing” or “position”. Statistics were first used by tax 
assessors to collect information for determining assets and assessing taxes. Nowadays, the 
application of statistics is broad and includes business, marketing, economics, agriculture, 
education, medicine and others. Statistics applied to medicine and other health disciplines is 
called biostatistics or biometrics. For those who would like to review or study this subject 
we recommend the book of Zar, 2010.  
Statistics is divided into two branches: descriptive and inferential. The goal of descriptive 
statistics is to organize and summarize data. And the goal of inferential statistics is to draw 
inferences and reach conclusions about a population, when only a sample from the 
population has been studied. A population is a complete set of observations, patients, 
measurements, and so forth. A sample is a subset of a certain population. 
To organize data and summarize their main characteristics we can use tables, graphs and 
quantitative indices. Tables are often used to present qualitative and quantitative data. 
Graphs are used widely to provide a visual display data. The bar diagram, histogram and 
frequency polygon are three graphic formats that are commonly used to present medical 
data. A table or a graph in which all values of a variable of interest are displayed with their 
corresponding frequency is called a frequency distribution, or simply a distribution. We shall 
see in the next subsection that in inferential statistics we are interested in a special type of 
distribution: a probability distribution.  
Quantitative indices are numbers that describe the center and the variation of a distribution. 
Quantitative indices that describe the center of a distribution are referred to as measures of 
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central tendency. The mean, known also as the arithmetic mean, median and mode are three 
common measures of central tendency. Quantitative indices that describe the variation or 
dispersion of a distribution are referred to as measures of dispersion. The range, variance and 
standard deviation are three common measures of dispersion. In medicine we usually work 
with other quantitative indices as risk difference, relative risk and odds ratio. To draw 
inferences and reach conclusions about a population, when only a sample from that 
population has been studied, we need to know probability, because we use statistical 
hypothesis testing and estimates. 
Statistical hypothesis tests can be parametric or nonparametric. Surveys of statistical methods 
used in journals indicate that the t test is one of the most commonly used statistical tests. The 
percentages of articles that use the t test range from 10% to more than 60%. Williams and 
colleagues (1997) noted a number of problems in using the t test. Welch and Gabbe (1996) 
found a number of errors in using the t test when a nonparametric procedure is called for. 
Thus, being able to use these techniques needs some skills in order to choose the correct 
statistical test. 
4.2 Parametric and nonparametric tests 
Combining the notion of a frequency distribution (descriptive statistics) and probability, we 
can explain what means a probability distribution. A probability distribution is a table or a 
graph that describes the probability of an event occurs. It describes what probably will 
happen instead of describing what really happened.  
A probability distribution can be discrete or continuous. An important example of a discrete 
probability distribution is the binomial distribution and an important example of a continuous 
distribution is the normal distribution.  
The binomial distribution is generated from a series of Bernoulli trials, named in honor of 
James Bernoulli (1654-1705). The binomial distribution is used when we have only two 
possible outcomes, which are mutually exclusive. For example, survived/died, 
male/female, adequate/inadequate, and others. 
The normal distribution is known also as the Gaussian distribution, in honor of Carl F. 
Gauss (1777-1855), who made significant contributions in the beginning of the 19th century 
to its development. The geometric representation of such a distribution is a symmetric and 
bell-shaped curve, known as the normal curve. The most important characteristic of the 
normal curve is the following: if perpendiculars are erected at the distance of one standard 
deviation above and one standard deviation below the mean, approximately 68% of the total 
area is between these perpendiculars, the x-axis and the curve. If perpendiculars are 
constructed at a distance of two standard deviations above and below the mean, 
approximately 95% of the total area is enclosed. If perpendiculars are set at a distance of 
three standard deviations to the left and right of the mean, approximately 99,7% of the total 
area is included, as shown in Figure 5. Since there is a correspondence between area and 
probability, we have information about the probability of data be located k standard 
deviation around the mean, for k = 1, 2 or 3. 
Comparing the above information with the information obtained by the Chebyshev 
theorem, we note that we can obtain more accurate results when data present a normal 
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distribution. The Chebyshev theorem claims that, for any probability distribution, the 
probability of data be located k standard deviation around the mean is, at least, 1-1/k2, 
where k is a positive number greater than 1. Table 4 compares the Chebyshev’s proportions 
with the proportions of a normal distribution, assuming k = 1, 2, 3 or 4. 
 
Fig. 5. Gaussian distribution. 
k Any distribution Normal distribution 
1 no information 68% 
2 ≥ 75% 95% 
3 ≥ 88% 99,7% 
4 ≥ 93,75 % 99,9% 
Table 4. Chebyshev’proportions compared with proportions of a normal distribution. 
If we decide to approximate clinical measurements by a normal curve, we are deciding to 
use a parametric hyphotesis test. A hypothesis test asks if an effect (difference) exists or not 
using statistics tests to verify the hypothesis that there is no difference. This is the null hypothesis 
and designated H0. The hypothesis that contradicts H0 is the alternative hypothesis and 
written HA. In the null hypothesis we use the words no difference or equal to and in the 
alternative hypothesis we use the words different from, less than or greater than. But let us 
mention that, in fact, we should say no statistical difference, statistically equal to, statistically 
different from, statistically less than or statistically greater than, because we are dealing with the 
probabilities of an event happens or not. When we retain HA (equivalently reject H0), we say 
the results are significant and when we retain H0 (equivalently reject HA), we say the results 
are not significant. Because we are dealing with probabilities, this implies in making two 
possible errors from four possible relations between statistical conclusions and real 
situations, as shown in Table 5. 
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Real difference 
Presence Absence 
Conclusion of the 
statistical test 
Results are 
significant 
True Type I error 
Results are not 
significant 
Type II error True 
Table 5. Relations between statistical conclusions and real situations. 
The two errors mentioned in the previous paragraph are known as Type I error and Type II 
error. A Type I error leads to a false positive conclusion. The probability of such an error 
occurs is noted by ┙. Mathematically, ┙ is a conditional probability: ┙ is the probability of 
reject H0 when there is no real difference. A Type II error leads to a false negative conclusion. 
The probability of such an error occurs is noted by ┚. Mathematically, ┚ is a conditional 
probability: ┚ is the probabilities of retain H0 when there is a real difference. 
Statistical tests are used to estimate the probability of a Type I error. In the literature, we 
usually use ┙ < 0.05. This means we are assuming a probability less than 0.05 of rejecting H0 
when there is no real difference between treatments, drugs or procedures. In other words, if 
the study were repeated one-hundred times, we probably would find five outcomes showing 
H0 should be accepted. 
There are several tests commonly used in the medical literature; they are resumed in Table 
6. Investigators should decide by using a parametric or a nonparametric test. This choice 
depends on the purpose of the study, the size of the sample, the type of the variables 
involved at the study, for instance. To use a parametric test we need to guarantee that the 
sampling distribution is normal or approximately normal. Because normal distribution has 
nice mathematical properties (bell-shaped, symmetric, and so on), using a parametric test 
leads to better statistical results compared with a nonparametric test. In other words, we say 
that nonparametric tests are less powerful, in the sense that they lead to a small probability 
to reject H0, when H0 is false. 
To test the statistical significance of the difference between ... 
Two or more proportions Chi-square nonparametric 
Two proportions Fisher’s exact parametric 
Two medians Mann-Whitney nonparametric 
Two means t-Student parametric 
More than two means Kruskal-Wallis (one-factor) nonparametric 
More than two means ANOVA (one-factor) parametric 
More than two means ANOVA (more-factors) parametric 
Table 6. Statistical tests usually used in the medical literature. 
When we use a statistic test we compute a p-value. The p-value is the probability of obtaining 
a result as extreme or more extreme than the sample value, assuming that the null 
hypothesis is true. The sample value is calculated. Depending on the test we use, there is a 
specific formula to calculate the sample value. Appropriate computer software can do such 
a calculation. 
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An increasing number of journals require that investigators include p-values in their 
manuscripts. When p-values are given, we are able to compare this probability to our own 
decision rule, which is the value of ┙. If the p-value is less than ┙, we say that the results are 
significant statistically. If the p-value is greater than ┙, we say that the results are not 
significant statistically. 
4.3 Statistical methods for evaluation of biomarkers in myelodysplastic syndrome  
Biostatistics gives us important tools to evaluate biomarkers in myelodysplastic syndrome 
and other diseases. Quantitative indices, estimates, hypothesis tests and survival tables are 
useful to point out biomarkers. We already discussed about quantitative indices and 
hypothesis tests. Let us make few comments about estimates and survival tables. 
In many situations, populations are so large that it is impossible to describe their central 
tendency and dispersion by studying 100% of their members, or by studying a sufficiently 
large portion of population to justify treating sample statistics as population parameters. In 
other situations, clinicians may study a new phenomenon with little basis to determine a 
population parameter. In these cases, we use estimates. Two types of estimates of a 
population parameter can be used: a point estimate and an interval estimate. A point 
estimate is a single numerical value of a sample statistic used to estimate the corresponding 
population parameter. Point estimates are not used widely because the value of some 
statistic, such as the sample mean, varies from sample to sample. So, an interval estimative 
is typically used. An interval estimate is a range of values which the parameter is likely to 
occur. Interval estimates are also called confidence intervals. 
Survival tables are used to describe prognosis. Prognosis is a prediction of the future course 
of a disease following its onset (Fletcher et al., 1988). We can describe the prognosis of a 
disease considering a fixed period of time (measures or taxes) or considering varying 
periods of time (survival tables). Table 7 shows the common measures used to describe 
prognosis when we consider a fixed period of time. 
Measure Definition 
Five-year survival 
Percentage of patients who survive for five years  from a certain 
time of the course of the disease 
Response 
Percentage of patients who show some evidence of improvement 
after a procedure or an intervention 
Remission Percentage of patients who start a period in which  the disease is 
not detectable 
Recurrence Percentage of patients who present reappearance of the disease 
after a free period  
Table 7. Common measures that describe prognosis. 
Survival tables can handle situations in which patients enter in some trial at different times 
and are followed for varying periods. We usually consider the length of time in a certain 
trial as being days, weeks or months and the end point may be, in the MDS case, death or 
the reappearance of the disease. The usual method used to construct a survival table is the 
Kaplan-Meier method. The curve obtained from the data presented in a survival table is 
called a survival curve. 
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The survival tables can allow us to compare two or more groups of patients. In this case, the 
first thing we should do is draw the survival curves for the two (or more) groups on the 
same graph. Statistical methods are important here, because we cannot make judgments 
simply on the basis of the amount of separation between the curves; a small difference may 
be statistically significant if the sample size is large, and a large difference may not if the 
sample size is small. We have mainly two methods to determine if the differences are 
statistically significant: the Wilcoxon rank sum test and the log rank test. Figure 6 shows 
comparative survival curves for pediatric and adult patients diagnosed with MDS treated 
with allogeneic hematopoietic stem cell transplantation (HSCT).  
 
Fig. 6. Overall survival of primary MDS patients treated with allogeneic HSCT, pediatric patients 
versus adult patients. 
In the Rodrigues et al (2010) study, the authors studied the methylation status of the 
p15INK4B and p16INK4A genes in 47 pediatric patients with MDS, its correlation with subtype, 
and the role of p15INK4B and p16INK4A in the evolution of MDS toward AML. The results 
obtained suggest that methylation of these genes is an epigenetic biomarker of pediatric 
disease evolution. The authors used some statistical tools presented here. For example, the 
correlation between p15INK4B gene methylation status and subtypes of pediatric primary 
MDS, considering initial stage RC, and later stages RAEB and RAEB-t, was assessed by the 
chi-square test, which is a nonparametric test. The statistical analysis suggested that the 
frequency of p15INK4B gene methylation was significantly higher in later stages of disease 
compared with the initial stage, with p-value < 0.003. The correlation between p16INK4A gene 
methylation status and subtypes of pediatric primary MDS was also assessed by the chi-
square test, with a slight modification. In fact, it is a correction factor, which is necessary 
when we have a small number of data. This is known as chi-square with continuity 
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correction or chi-square with Yates’correction. The results obtained suggested that the 
frequency of p16INK4A gene methylation was found more frequently in subtypes 
characterizing the advanced stages of MDS, with p-value < 0.05.  
Quantitative analysis to evaluate whether there was a correlation between percentage of 
p15INK4B methylation and MDS subtypes was performed in (Rodrigues et al., 2010). The 
percentage of p15INK4B methylation was higher in RAEB and RAEB-t compared to RC. The 
authors used ANOVA (one-factor) and obtained a p-value < 0,0001. The same result was 
obtained for the p16INK4A gene.  The authors used ANOVA (more-factors) to verify that 
QMS-PCR method was more sensitive than COBRA method, obtaining a p-value < 0.0001, 
although both methods were accurate in showing a correlation between the subtypes of 
disease and the level of methylation.  
The Mann-Whitney test was also used. The authors calculated the mean time of disease 
evolution in patients who had p15INK4B methylation and in patients with no p15INK4B 
methylation. The results were 4.6 months and 14.6 months, respectively. The mean time of 
disease evolution for patients who had p15INK4B methylation, therefore, was three times less 
than the mean time of evolution for patients who had no p15INK4B methylation, which was 
statistically significant by using Mann-Whitney (p-value < 0.02). 
Many concepts and theorems that are not familiar to medical professionals are used in 
Statistics, as null hypothesis, regression, parametric tests, the central limit theorem, Bayes 
theorem and so on. Of course, medical professionals should put away the complexity of 
such concepts and the mathematics is behind all this theory, although only mathematics 
could explain rigorously why these techniques really work. Nevertheless we must say that 
Statistics is an important tool that can help making decisions and must be used if the 
statistics outcomes are clinically meaningful. Accumulated experience and specific 
knowledge must be combined with results from statistical tests to assess the usefulness of a 
particular outcome or medical decision.  
5. Conclusion 
The field of cancer epigenetics is evolving rapidly. Advances in the understanding of 
chromatin structure, histone modifications, DNA methylation and transcriptional activity 
have resulted in an increasingly integrated view of epigenetics. These discoveries lead to the 
development of new treatments in cancer using epigenetic therapies. The MDS comprises a 
complex spectrum of hematopoietic stem cell disorders, where the study of epigenetics has 
brought new knowledge about the development and evolution of this disease to AML. 
Other important points in epigenetics studies in MDS were the introduction of the 
treatments using hypomethylant drugs and histone deacethylases inhibitors. The MDS may 
be considered a good model to study the epigenetics in the cancer pathogenesis research 
and the applicability in clinical. The identification of biomarkers of diagnosis and prognosis 
in MDS will possibility the elaboration of new classification and score prognostic systems 
and will help to understand the different pathways involved in the MDS pathogenesis. With 
the advance of the technologies involving epigenome projects, future research in the 
epigenetic therapies will be the development of inhibitors with specificity to particular 
biomarkers. 
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